BiotechTube
Home/Protara Therapeutics/Julianne Averill
JA

Julianne Averill

Chief Financial Officer

Protara Therapeutics

Therapeutic Areas

OncologyRare DiseasesGastroenterology

Protara Therapeutics Pipeline

DrugIndicationPhase
TARA-002Non-Muscle Invasive Bladder Cancer (NMIBC), BCG-unresponsive carcinoma in situ (CIS) with/without papillary tumorsPhase 2
IV Choline ChlorideIntestinal Failure-Associated Liver Disease (IFALD)Phase 2

Leadership Team at Protara Therapeutics

JS
Jesse Shefferman
Chief Executive Officer
BM
Blaine McKee, Ph.D.
Chief Business Officer
HF
Hannah Frye, MD
Chief Medical Officer
RG
Richard G. Baum
Chief Operating Officer & General Counsel
ML
Michael L. Levitt
Chairman of the Board
PF
Patrick Fabbio
Director
RD
Richard Dean
Director
RJ
Robert J. Spiegel, M.D.
Director
JR
James R. Sulat
Director
View full Protara Therapeutics profile